Active Ingredient History
The mitomycins are a family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae. One of these compounds, mitomycin C, finds use as a chemotherapeutic agent by virtue of its antitumour activity. Mitomycin C has also been used topically rather than intravenously in several areas. The first is cancers, particularly bladder cancers and intraperitoneal tumours. It is now well known that a single instillation of this agent within 6 hours of bladder tumor resection can prevent recurrence. The second is in eye surgery where mitomycin C 0.02% is applied topically to prevent scarring during glaucoma filtering surgery and to prevent haze after PRK or LASIK; mitomycin C has also been shown to reduce fibrosis in strabismus surgery. The third is in esophageal and tracheal stenosis where application of mitomycin C onto the mucosa immediately following dilatation will decrease re-stenosis by decreasing the production of fibroblasts and scar tissue. Mitomycin C is a potent DNA crosslinker. A single crosslink per genome has shown to be effective in killing bacteria. This is accomplished by reductive activation of mitomycin to form a mitosene, which reacts successively via N-alkylation of two DNA bases. Both alkylations are sequence specific for a guanine nucleoside in the sequence 5'-CpG-3'. Potential bis-alkylating heterocylic quinones were synthetised in order to explore their antitumoral activities by bioreductive alkylation. Mitomycin is also used as a chemotherapeutic agent in glaucoma surgery. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Gastrointestinal Neoplasms (approved 2012)
Pancreatic Neoplasms (approved 2012)
Adenocarcinoma (Phase 2)
Anastomotic Leak (Phase 2)
Angiography (Early Phase 1)
Anus Diseases (Phase 3)
Anus Neoplasms (Phase 3)
Appendiceal Neoplasms (Phase 2)
Appendix (Phase 2)
Biliary Tract Neoplasms (Phase 2)
Breast Neoplasms (Phase 3)
Carcinoma (Phase 3)
Carcinoma, Hepatocellular (Phase 3)
Carcinoma in Situ (Phase 3)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Ovarian Epithelial (Phase 2)
Carcinoma, Renal Cell (Phase 3)
Carcinoma, Squamous Cell (Phase 3)
Carcinoma, Transitional Cell (Phase 3)
Cataract (Phase 2)
Cholangiocarcinoma (Phase 2)
Cholangitis, Sclerosing (Phase 2)
Colorectal Neoplasms (Phase 3)
Conjunctival Neoplasms (Phase 4)
Corneal Diseases (Phase 4)
Corneal Opacity (Phase 2/Phase 3)
Esophageal Neoplasms (Phase 2)
Esophageal Stenosis (Phase 2)
Esophagogastric Junction (Phase 2)
Eye Diseases (Early Phase 1)
Fallopian Tube Neoplasms (Phase 2)
Gastrointestinal Neoplasms (Phase 2)
General Surgery (Phase 2)
Glaucoma ()
Glaucoma, Angle-Closure (Phase 3)
Glaucoma, Neovascular (Phase 3)
Glaucoma, Open-Angle (Phase 4)
Hamartoma (Phase 2)
Head and Neck Neoplasms (Phase 4)
HIV Infections (Phase 2)
Keratoconus (Phase 2)
Leukemia (Phase 1)
Liver Neoplasms (Phase 2)
Lung Neoplasms (Phase 3)
Mesothelioma, Malignant (Phase 3)
Mycobacterium (Phase 3)
Myopia (Phase 4)
Nasal Cavity (Phase 2)
Nasopharyngeal Carcinoma (Phase 3)
Neoplasm Metastasis (Phase 3)
Neoplasm Recurrence, Local (Phase 3)
Neoplasms ()
Neoplasms by Site (Phase 3)
Neoplasms, Squamous Cell (Phase 3)
Neuroendocrine Tumors (Phase 3)
Optic Nerve (Early Phase 1)
Oropharyngeal Neoplasms (Phase 4)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 3)
Pediatrics (Phase 3)
Peritoneal Neoplasms (Phase 3)
Postoperative Complications (Phase 3)
Presbyopia (Phase 4)
Pterygium (Phase 4)
Rectal Neoplasms (Phase 3)
Refractive Errors (Phase 4)
Sarcoma (Phase 2)
Sinusitis (Phase 3)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Diseases (Phase 1)
Stomach Neoplasms (Phase 3)
Survival (Phase 2)
Tissue Adhesions (Phase 2)
Trabeculectomy (Phase 3)
Ureteral Neoplasms (Phase 2)
Urethral Neoplasms (Phase 2)
Urethral Stricture (Phase 1/Phase 2)
Urinary Bladder Diseases (Phase 3)
Urinary Bladder Neoplasms (Phase 4)
Urogenital Neoplasms (Phase 3)
Urologic Diseases (Phase 3)
Urologic Neoplasms (Phase 3)
Uterine Cervical Neoplasms (Phase 3)
Uveitis (Phase 3)
Wound Healing (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
